10 results on '"Xinhua Xie"'
Search Results
2. A nation-wide multicenter retrospective study of the epidemiological, pathological and clinical characteristics of breast cancer in situ in Chinese women in 1999 - 2008.
- Author
-
Yanan Kong, Lu Yang, Hailin Tang, Ning Lv, Xinhua Xie, Jing Li, Jiaoli Guo, Laisheng Li, Minqin Wu, Jie Gao, Hongjian Yang, Zhonghua Tang, Jianjun He, Bin Zhang, Hui Li, Youlin Qiao, and Xiaoming Xie
- Subjects
Medicine ,Science - Abstract
BackgroundCompared with invasive breast cancer, breast cancer in situ (BCIS) is seldom life threatening. However, an increasing incidence has been observed in recent years over the world. The purpose of our study is to investigate the epidemiological, clinical and pathological profiles of BCIS in Chinese women from 1999-2008.MethodsFour thousand and two hundred-eleven female breast cancer (BC) patients were enrolled in this hospital-based nation-wide and multi-center retrospective study. Patients were randomly selected from seven hospitals in seven representative geographical regions of China between 1999 and 2008. The epidemiological, clinical and pathological data were collected based on the designed case report form (CRF).ResultsThere were one hundred and forty-three BCIS cases in four thousand and two hundred-eleven BC patients (3.4%). The mean age at diagnosis was 48.3 years and BCIS peaked in age group 40-49 yrs (39.9%). The most common subtype was ductal carcinoma in situ (DCIS) (88.0%). 53.8% were positive for estrogen receptor (ER). Human epidermal growth factor receptor 2 (HER2) positive status was observed in 23.8% of patients. All patients underwent surgeries and 14.7% of them had breast conservation therapies (BCT) (21/143), but 41.9% accepted chemotherapy (64/143). Much less patients underwent radiotherapy (16.0%, 23/143) and among patients who had BCT, 67% accepted radiotherapy (14/21). Endocrine therapy was taken in 44.1% patients (63/143).ConclusionsThe younger age of BCIS among Chinese women than Western countries and increasing number of cases pose a great challenge. BCT and endocrine therapy are under great needs.
- Published
- 2013
- Full Text
- View/download PDF
3. Correction: MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1.
- Author
-
Jie Gao, Laisheng Li, Minqing Wu, Min Liu, Xinhua Xie, Jiaoli Guo, Hailin Tang, and Xiaoming Xie
- Subjects
Medicine ,Science - Published
- 2013
- Full Text
- View/download PDF
4. MiR-26a inhibits proliferation and migration of breast cancer through repression of MCL-1.
- Author
-
Jie Gao, Laisheng Li, Minqing Wu, Min Liu, Xinhua Xie, Jiaoli Guo, Hailin Tang, and Xiaoming Xie
- Subjects
Medicine ,Science - Abstract
Breast cancer is the most commonly malignancies in women. MicroRNAs are a family of small non-coding RNAs 18-25 nucleotides in length that post-transcriptionally modulate gene expression. MiR-26a has been reported as a tumor suppressor microRNA in breast cancer, which is attributed mainly to targeting of MTDH and EZH2, however, the expression profile and therapeutic potential of miR-26a is still unclear. Here we demonstrate that miR-26a is down-regulated in breast cancer cells and clinical specimens and its modulation in breast cancer cells regulates cell proliferation, colony formation, migration and apoptosis. MCL-1, an anti-apoptotic member of the Bcl-2 family, as novel targets of miR-26a was found to be in reverse correlation with ectopic expression of miR-26a and knockdown of MCL-1 phenocopied the effect of miR-26a in breast cancer cell lines. It was further explored that miR-26a increased sensitivity of breast cancer cells to paclitaxel in which MCL-1 was involved. Thus, miR-26a impacts on cell proliferation and migration of breast cancer by regulating several carcinogenesis-related processes, including a novel mechanism involving the targeting of MCL-1.
- Published
- 2013
- Full Text
- View/download PDF
5. Cytokeratin19-2g2, a novel fragment of cytokeratin19 in serum, indicating a more invasive behavior and worse prognosis in breast cancer patients.
- Author
-
Yanan Kong, Junye Wang, Wanli Liu, Qiaolun Chen, Juan Yang, Weidong Wei, Mingqing Wu, Lu Yang, Xinhua Xie, Ning Lv, Jiaoli Guo, Laisheng Li, Jie Gao, Xiaoming Xie, and Shuqin Dai
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Various studies have been searching for new tumor biomarkers for breast cancer for years. However, so far, few markers have been proved clinically useful except CA153. Based on knowledge that most adenocarcinomas including breast carcinoma expressed Cytokeratin19, the authors studied CK19-2G2,a novel fragment of cytokeratin19 shedding into serum in breast cancer patients. PATIENTS AND METHODS: The serum samples of four hundred and seventeen patients including three hundred and three (fifty-four DCIS and two hundred and forty-nine stage I-III) PBC patients and one hundred and fourteen MBC patients, eighty-one healthy controls and twenty-one breast benign disease patients were provided for measurement of CK19-2G2, CEA and CA153.The correlation between clinicopathological characters, prognosis and CK19-2G2 levels was further studied. RESULTS: The serum CK19-2G2 levels in breast cancer patients were significantly higher than that in healthy and benign controls. For breast cancer patients, CK19-2G2 levels in MBC were significantly higher than that in PBC patients. The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients. Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status. Multivariate analysis revealed that high serum CK19-2G2 level was an independent factor for relapse (P = 0.029) and death (P = 0.040) in breast cancer patients. CONCLUSION: Serum CK19-2G2 may be an independent indicator for prognosis and a candidate marker for monitoring metastasis in breast cancer.
- Published
- 2013
- Full Text
- View/download PDF
6. BikDDA, a mutant of Bik with longer half-life expression protein, can be a novel therapeutic gene for triple-negative breast cancer
- Author
-
Minqing Wu, Feng Ye, Shiping Jiao, Xinhua Xie, Xiaoming Xie, and Hailin Tang
- Subjects
Epidemiology ,Genetic enhancement ,Mutant ,Cancer Treatment ,lcsh:Medicine ,Apoptosis ,Triple Negative Breast Neoplasms ,Biochemistry ,Metastasis ,Molecular Cell Biology ,Breast Tumors ,Drug Discovery ,Medicine and Health Sciences ,Molecular Targeted Therapy ,Phosphorylation ,Extracellular Signal-Regulated MAP Kinases ,lcsh:Science ,Triple-negative breast cancer ,Molecular Epidemiology ,Multidisciplinary ,Cell Death ,Gene Therapy ,Transfection ,Middle Aged ,Prognosis ,Oncology ,Chemotherapy, Adjuvant ,Cell Processes ,Female ,Fluorouracil ,Cancer Epidemiology ,Half-Life ,Research Article ,Drug Research and Development ,bcl-X Protein ,Biology ,Mitochondrial Proteins ,Breast cancer ,Cell Line, Tumor ,Breast Cancer ,Biomarkers, Tumor ,medicine ,Humans ,Molecular Biology Techniques ,Molecular Biology ,Clinical Genetics ,Pharmacology ,lcsh:R ,Membrane Proteins ,Biology and Life Sciences ,Cancers and Neoplasms ,Cell Biology ,medicine.disease ,Drug Resistance, Neoplasm ,Multivariate Analysis ,Immunology ,Cancer research ,Myeloid Cell Leukemia Sequence 1 Protein ,Mutant Proteins ,lcsh:Q ,Apoptosis Regulatory Proteins - Abstract
Our previous studies showed that BikDD, a constitutively active mutant form of Bik, exhibited powerful antitumor effects in preclinical pancreatic, lung and breast cancer models. Howerver, the antitumor activity of BikDD in triple-negative breast cancer (TNBC) is unknown. Here we show that aberrant expression of p-ERK1/2 was a meaningful molecular phenotype in TNBC patients, and can be an obstacle for treatment because of the converse correlation with Bik. A novel mutant, BikDDA, in which Ser124 was changed to Alanine to block BikDD phosphorylation by p-ERK1/2 prevented subsequent ubiquitin-proteasome degradation. BikDDA showed a prolonged half-life and enhanced pro-apoptotic ability in TNBC cells compared with BikDD. Moreover, aberrant expression of p-ERK1/2 was associated with 5-fluorouracil resistance in breast cancer patients and BikDDA enhanced the therapeutic effects of 5-fluorouracil in vitro.
- Published
- 2014
7. MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1
- Author
-
Min Liu, Xiaoming Xie, Jie Gao, Minqing Wu, Xinhua Xie, Laisheng Li, Jiaoli Guo, and Hailin Tang
- Subjects
Multidisciplinary ,business.industry ,Science ,lcsh:R ,Correction ,lcsh:Medicine ,medicine.disease ,Breast cancer ,Text mining ,Expression analysis ,medicine ,Cancer research ,Medicine ,lcsh:Q ,lcsh:Science ,skin and connective tissue diseases ,business ,Psychological repression ,Normal breast - Abstract
In Figure 1, not all of the data is included. The incorrect version of the figure represents miR-26a expression analysis in 20 breast cancer specimens and 15 normal breast tissues. The revised version includes 52 breast cancer specimens and 29 normal breast tissues. Please see the revised version of Figure 1 here
- Published
- 2013
8. A nation-wide multicenter retrospective study of the epidemiological, pathological and clinical characteristics of breast cancer in situ in Chinese women in 1999 - 2008
- Author
-
Lu Yang, Ning Lv, Hong Jian Yang, Zhonghua Tang, Hui Li, Minqin Wu, Yanan Kong, Hailin Tang, Jie Gao, Xiaoming Xie, Jing Li, Jiaoli Guo, Xinhua Xie, Laisheng Li, Jianjun He, Bin Zhang, and You-Lin Qiao
- Subjects
Oncology ,Adult ,medicine.medical_specialty ,Pathology ,Science ,Breast Neoplasms ,Young Adult ,Breast cancer ,Risk Factors ,Internal medicine ,Epidemiology ,Epidemiology of cancer ,medicine ,Mammography ,Humans ,Young adult ,Aged ,Retrospective Studies ,Aged, 80 and over ,Multidisciplinary ,medicine.diagnostic_test ,business.industry ,Incidence (epidemiology) ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Carcinoma, Intraductal, Noninfiltrating ,Population Surveillance ,Medicine ,Hormonal therapy ,Female ,business ,Research Article - Abstract
BackgroundCompared with invasive breast cancer, breast cancer in situ (BCIS) is seldom life threatening. However, an increasing incidence has been observed in recent years over the world. The purpose of our study is to investigate the epidemiological, clinical and pathological profiles of BCIS in Chinese women from 1999-2008.MethodsFour thousand and two hundred-eleven female breast cancer (BC) patients were enrolled in this hospital-based nation-wide and multi-center retrospective study. Patients were randomly selected from seven hospitals in seven representative geographical regions of China between 1999 and 2008. The epidemiological, clinical and pathological data were collected based on the designed case report form (CRF).ResultsThere were one hundred and forty-three BCIS cases in four thousand and two hundred-eleven BC patients (3.4%). The mean age at diagnosis was 48.3 years and BCIS peaked in age group 40-49 yrs (39.9%). The most common subtype was ductal carcinoma in situ (DCIS) (88.0%). 53.8% were positive for estrogen receptor (ER). Human epidermal growth factor receptor 2 (HER2) positive status was observed in 23.8% of patients. All patients underwent surgeries and 14.7% of them had breast conservation therapies (BCT) (21/143), but 41.9% accepted chemotherapy (64/143). Much less patients underwent radiotherapy (16.0%, 23/143) and among patients who had BCT, 67% accepted radiotherapy (14/21). Endocrine therapy was taken in 44.1% patients (63/143).ConclusionsThe younger age of BCIS among Chinese women than Western countries and increasing number of cases pose a great challenge. BCT and endocrine therapy are under great needs.
- Published
- 2013
9. MiR-26a Inhibits Proliferation and Migration of Breast Cancer through Repression of MCL-1
- Author
-
Xiaoming Xie, Jie Gao, Xinhua Xie, Jiaoli Guo, Hailin Tang, Minqing Wu, Min Liu, and Laisheng Li
- Subjects
Oncology ,Cancer Treatment ,lcsh:Medicine ,Apoptosis ,Cell Movement ,Molecular Cell Biology ,Breast Tumors ,Signaling in Cellular Processes ,lcsh:Science ,Apoptotic Signaling ,Gene knockdown ,Multidisciplinary ,EZH2 ,MTDH ,Gene Therapy ,Middle Aged ,Medicine ,Epigenetics ,Female ,Cell Movement Signaling ,Research Article ,Signal Transduction ,Adult ,medicine.medical_specialty ,Paclitaxel ,Cell Survival ,Down-Regulation ,Breast Neoplasms ,Biology ,Breast cancer ,Cell Line, Tumor ,Internal medicine ,microRNA ,Genetics ,medicine ,Animals ,Humans ,Cell Proliferation ,Base Sequence ,Cell growth ,lcsh:R ,Cancers and Neoplasms ,medicine.disease ,MicroRNAs ,Nasopharyngeal carcinoma ,Cancer research ,Myeloid Cell Leukemia Sequence 1 Protein ,lcsh:Q ,Ectopic expression - Abstract
Breast cancer is the most commonly malignancies in women. MicroRNAs are a family of small non-coding RNAs 18-25 nucleotides in length that post-transcriptionally modulate gene expression. MiR-26a has been reported as a tumor suppressor microRNA in breast cancer, which is attributed mainly to targeting of MTDH and EZH2, however, the expression profile and therapeutic potential of miR-26a is still unclear. Here we demonstrate that miR-26a is down-regulated in breast cancer cells and clinical specimens and its modulation in breast cancer cells regulates cell proliferation, colony formation, migration and apoptosis. MCL-1, an anti-apoptotic member of the Bcl-2 family, as novel targets of miR-26a was found to be in reverse correlation with ectopic expression of miR-26a and knockdown of MCL-1 phenocopied the effect of miR-26a in breast cancer cell lines. It was further explored that miR-26a increased sensitivity of breast cancer cells to paclitaxel in which MCL-1 was involved. Thus, miR-26a impacts on cell proliferation and migration of breast cancer by regulating several carcinogenesis-related processes, including a novel mechanism involving the targeting of MCL-1.
- Published
- 2013
10. Cytokeratin19-2g2, a Novel Fragment of Cytokeratin19 in Serum, Indicating a More Invasive Behavior and Worse Prognosis in Breast Cancer Patients
- Author
-
Lu Yang, Juan Yang, Weidong Wei, Xinhua Xie, Jiaoli Guo, Laisheng Li, Shuqin Dai, Junye Wang, Mingqing Wu, Xiaoming Xie, Jie Gao, Ning Lv, Wanli Liu, Yanan Kong, and Qiaolun Chen
- Subjects
Adult ,CA15-3 ,Oncology ,medicine.medical_specialty ,lcsh:Medicine ,Breast Neoplasms ,Metastasis ,Tumor Biomarkers ,Breast cancer ,Carcinoembryonic antigen ,Diagnostic Medicine ,Internal medicine ,Breast Cancer ,Breast Tumors ,Biomarkers, Tumor ,Pathology ,Cancer Detection and Diagnosis ,Early Detection ,Humans ,Medicine ,Neoplasm Invasiveness ,lcsh:Science ,skin and connective tissue diseases ,Neoplasm Staging ,Keratin-19 ,Multidisciplinary ,biology ,business.industry ,Mucin-1 ,lcsh:R ,Endocrine therapy ,Obstetrics and Gynecology ,Cancers and Neoplasms ,Middle Aged ,Prognosis ,medicine.disease ,Carcinoembryonic Antigen ,biology.protein ,Female ,lcsh:Q ,Neoplasm staging ,business ,Breast carcinoma ,Biomarkers ,Cancer Screening ,Research Article ,General Pathology - Abstract
BACKGROUND: Various studies have been searching for new tumor biomarkers for breast cancer for years. However, so far, few markers have been proved clinically useful except CA153. Based on knowledge that most adenocarcinomas including breast carcinoma expressed Cytokeratin19, the authors studied CK19-2G2,a novel fragment of cytokeratin19 shedding into serum in breast cancer patients. PATIENTS AND METHODS: The serum samples of four hundred and seventeen patients including three hundred and three (fifty-four DCIS and two hundred and forty-nine stage I-III) PBC patients and one hundred and fourteen MBC patients, eighty-one healthy controls and twenty-one breast benign disease patients were provided for measurement of CK19-2G2, CEA and CA153.The correlation between clinicopathological characters, prognosis and CK19-2G2 levels was further studied. RESULTS: The serum CK19-2G2 levels in breast cancer patients were significantly higher than that in healthy and benign controls. For breast cancer patients, CK19-2G2 levels in MBC were significantly higher than that in PBC patients. The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients. Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status. Multivariate analysis revealed that high serum CK19-2G2 level was an independent factor for relapse (P = 0.029) and death (P = 0.040) in breast cancer patients. CONCLUSION: Serum CK19-2G2 may be an independent indicator for prognosis and a candidate marker for monitoring metastasis in breast cancer.
- Published
- 2013
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.